Create More Value Than Meets the Eye, Initiating Buy $10 TP • Conclusions — We are initiating coverage with a Buy rating and $10 TP. In our view. Tamsulosin DRS. slow release granules, and Tamsulosin XR capsules have potential to be value drivers for the stock based on their differentiated profile including

Inc. Veru Inc. (Veru) is a biopharmaceutical company focused on urology and oncology. The company is currently developing drug product candidates: Tamsulosin DRS, slow release granules, and Tamsulosin XR capsules for lower urinary tract symptoms of benign prostatic hyperplasia (BPH) (NDA planned 2018), Solife